跳至主導覽
跳至搜尋
跳過主要內容
臺北醫學大學 首頁
說明與常見問題
連結會在新分頁中打開
English
中文
在 臺北醫學大學 搜尋內容
首頁
專家檔案
研究單位
專案
研究成果
資料集
活動
胸腔內科
醫學系
內科學科
電話
+886-2-22490088#2714
電子郵件
[email protected]
網站
http://medschool.tmu.edu.tw/main.php
郵寄地址
在地圖上顯示
概覽
指紋
網路
專家檔案
(19)
專案
(154)
研究成果
(1101)
資料集
(46)
指紋
查看啟用 胸腔內科 的研究主題。這些主題標籤來自此機構會員的作品。共同形成了獨特的指紋。
排序方式
重量
按字母排序
Medicine and Dentistry
Tuberculosis
85%
Obstructive Sleep Apnea
53%
Chronic Obstructive Pulmonary Disease
47%
Multidrug Resistant Tuberculosis
44%
Non Small Cell Lung Cancer
44%
Epidermal Growth Factor Receptor
42%
Lung
41%
Cohort Analysis
38%
Meta-Analysis
35%
Lung Cancer
34%
Particular Matter 2.5
33%
Asthma
27%
Lung Tuberculosis
25%
Drug Resistant Tuberculosis
23%
Atmospheric Aerosol
23%
Rifampicin
21%
Chemotherapy
20%
Tuberculosis Treatment
20%
Systematic Review
18%
Hazard Ratio
18%
Odds Ratio
17%
Lung Adenocarcinoma
17%
Treatment Outcome
16%
Infection
16%
Diseases
16%
Emphysema
16%
K-Complex
15%
COVID-19
15%
Quinolone Derivative
13%
Inflammation
13%
Non-Small Cell Lung Cancer
12%
Malignant Neoplasm
12%
Tuberculostatic Agent
12%
Pleura Effusion
12%
Chronic Kidney Disease
11%
Neoplasm
11%
Isoniazid
11%
4 Iodo 2,5 Dimethoxyamphetamine
10%
Observational Study
10%
Cross Sectional Study
10%
Patient-Data
10%
Overall Survival
10%
Body Mass Index
10%
Adverse Event
10%
Diabetes Mellitus
10%
Biological Marker
10%
Progression Free Survival
9%
Effusion
9%
Randomized Controlled Trial
9%
Recurrent Disease
9%
Heart Rate Variability
9%
Fine Particulate Matter
9%
Epidermal Growth Factor Receptor Kinase Inhibitor
9%
Signal Transduction
9%
Tyrosine-Kinase Inhibitor
9%
Retrospective Cohort Study
8%
Health Care Cost
8%
Computer Assisted Tomography
8%
Prevalence
8%
Hypopnea
8%
Pneumonia
8%
Platinum
8%
Polysomnography
8%
Corticosteroid
8%
Apnea
8%
Mycobacterium Tuberculosis
8%
Adenocarcinoma
8%
Low Drug Dose
7%
Human Immunodeficiency Virus
7%
Continuous Positive Airway Pressure
7%
Cancer
7%
Artificial Intelligence
7%
Macrophage
7%
Oral
7%
Polycyclic Aromatic Hydrocarbon
7%
Drug Resistance
7%
Comorbidity
6%
Clinician
6%
Severe Acute Respiratory Syndrome Coronavirus 2
6%
Phosphotransferase
6%
Logistic Regression Analysis
6%
Diabetes
6%
Mortality Rate
6%
Extensively Drug Resistant Tuberculosis
6%
Hippo Signaling
6%
Lung Function
6%
Systemic Lupus Erythematosus
6%
Climatic Change
6%
Climate Change
6%
Silo-Filler's Disease
6%
Oxygen Desaturation
6%
Low and Middle Income Countries
6%
Body Fat
6%
Entrectinib
6%
Drug Sensitivity
6%
Tumor Cell
6%
Proportional Hazards Model
6%
Bedaquiline
6%
Genetics
5%
Blood Pressure
5%
Pharmacology, Toxicology and Pharmaceutical Science
Chronic Obstructive Lung Disease
65%
Epidermal Growth Factor Receptor
60%
Lung Cancer
55%
Non Small Cell Lung Cancer
47%
Inflammation
36%
Cohort Study
34%
Tuberculosis
32%
Lung Adenocarcinoma
28%
Malignant Neoplasm
25%
Nuclear Factor
23%
Alternative Complement Pathway C3 C5 Convertase
23%
Protein Kinase B
23%
Polycyclic Aromatic Hydrocarbon
21%
Asthma
20%
Phosphotransferase
20%
Epidermal Growth Factor Receptor Kinase Inhibitor
20%
Sleep Disordered Breathing
20%
Cyclooxygenase 2
19%
Connective Tissue Growth Factor
19%
Interleukin 6
18%
Rat
18%
Pneumonia
17%
Thrombin
17%
Chemotherapy Regimens
16%
Adverse Event
16%
Biological Marker
16%
Neoplasm
16%
Diseases
15%
Cytotoxicity
15%
Chronic Kidney Failure
15%
Protein Kinase C
15%
Protein Tyrosine Kinase Inhibitor
14%
Reactive Oxygen Metabolite
13%
Corticosteroid
13%
Plasminogen Activator Inhibitor 1
12%
Mitogen Activated Protein Kinase
12%
Progression Free Survival
12%
Cancer Growth Factor
11%
Emphysema
11%
Tumor Necrosis Factor
11%
Cytokine
11%
Zinc Oxide Nanoparticle
10%
Uridine Triphosphate
10%
Endothelin 1
10%
Tuberculostatic Agent
10%
Randomized Controlled Trial
10%
Fibrosis
9%
Isoniazid
9%
Nitric Oxide
9%
Overall Survival
9%
Vaccination
9%
Erlotinib
9%
Placebo
9%
Pleura Effusion
8%
Osimertinib
8%
Ovalbumin
8%
Histone Deacetylase Inhibitor
8%
Interleukin 8
8%
Cell Viability
8%
Multi-Drug-Resistant Tuberculosis
8%
Organic Carbon
8%
Luciferase
8%
Small Interfering RNA
8%
Platinum
7%
Lipopolysaccharide
7%
Immunotherapy
7%
Peptidoglycan
7%
Influenza
7%
Transcription Factor AP 1
7%
Effusion
7%
Quinolone Derivative
7%
Observational Study
7%
Fibrinogen
7%
Receptor
7%
Pharmacokinetics
7%
Disease Exacerbation
6%
Lactate Dehydrogenase
6%
Cisplatin
6%
Adenocarcinoma
6%
Calcium Ion
6%
Prevalence
6%
Recurrent Disease
6%
Monotherapy
6%
Systemic Lupus Erythematosus
6%
Cigarette Smoke
6%
Phosphotransferase Inhibitor
6%
Rifampicin
6%
Gefitinib
6%
Infection
6%
Durvalumab
6%
Microbiome
6%
Lung Tuberculosis
6%
Respiratory Tract Allergy
5%
Uvomorulin
5%
Nephrotoxicity
5%
Western Blot
5%
Immune Checkpoint Inhibitor
5%
Deterioration
5%
Interferon
5%
Pleural Fibrosis
5%
Immunology and Microbiology
Lung
100%
Asthma
46%
Particulate Matter
35%
Infectious Disease
32%
Infection
32%
Inflammation
28%
Phosphotransferase
23%
Kinase
23%
COVID-19
22%
Mycobacterium Tuberculosis
22%
Interleukin 6
19%
Airway
19%
Blood Plasma
14%
Severe Acute Respiratory Syndrome Coronavirus 2
13%
Macrophage
13%
Prevalence
13%
Connective Tissue Growth Factor
12%
Neutrophil
12%
T Cell
12%
Oxidative Stress
12%
Epidermal Growth Factor
11%
Tumor Necrosis Factor
11%
Tyrosine
10%
Allergic Asthma
10%
Immunocompetent Cell
9%
Overall Survival
9%
Proteomics
9%
Nontuberculous mycobacteria
9%
Cancer Cell
9%
Susceptibility
9%
Lung Fibroblast
8%
Inflammation Response
8%
Immune Response
8%
Blood Level
8%
Comorbidity
8%
Breathing
7%
Dendritic Cell
7%
Programmed Death 1 Ligand 1
7%
Immunotherapy
7%
Signal Transduction
7%
Epithelium
7%
Endothelin
7%
Pretreatment
7%
Interleukin 17
7%
Regulatory T Cell
7%
Cytokine
6%
Endothelial Cells
6%
Mortality Rate
6%
Eczema
6%
Complement Factor B
6%
Bronchoalveolar Lavage Fluid
6%
In Vitro
6%
Cadherin
6%
Rat
6%
Interleukin 8
6%
Cytotoxicity
6%
Eosinophil
6%
phosphorylation
6%
Morbidity
6%
Gene Expression
5%
Immunoglobulin E
5%
Antigen
5%
Upregulation
5%
Influenza
5%
Circulating Tumor Cell
5%
Dioxygen
5%
Interferon Type I
5%
Forced Expiratory Volume
5%
Hemodialysis
5%
Programmed Cell Death
5%